Topic:

R&D

Latest Headlines

Latest Headlines

Puma shrugs off an 'expected' Phase II failure for its breast cancer drug

Puma Biotechnology's closely watched neratinib failed to beat out the blockbuster Herceptin in a mid-stage breast cancer trial, a miss the company said was no surprise as it touted success on a secondary goal.

NHS sets out vision for IT-enabled, research-facilitating future

The U.K. government has set out its vision for how the National Health Service will transform into a tech-savvy, research-enabling organization by 2020. As part of the wide-reaching strategy, NHS England will create "test bed" sites at which bioinformatics approaches and other tools will be tested.

Venter's HLI inks deal to access registry of 11,000 twins

J. Craig Venter's Human Longevity, Inc. has added another piece to the data tapestry it is creating. The new addition is a registry of 11,000 twins, complete with phenotypic information and paired samples.

Are drug developers over-relying on genomics?

Over the past few decades, the harsh realities of complex biology have brought back to Earth some pie-in-the-sky projections about the value of genomics in biotech R&D. But the industry still devotes the vast majority of research spending to target-based drug development, an imbalance that could be a factor in Big Pharma's slumping efficiency rates.

Sanofi execs prep their pitch on a post-Viehbacher R&D strategy

One of the primary roles for any Big Pharma CEO is to act as a chief defender of the pipeline. Just months ago, Chris Viehbacher boldly asserted that Sanofi had one of the top 5 pipelines in the industry, if you added in some top programs among its close development partners.

Study: Universal E. coli vaccine appears possible thanks to limited number of strains

Development of a vaccine to protect against the Escherichia coli (E. coli) bacterium has been stymied because the genetic structure of the many strains of E. coli varied hugely. But according to a new study, the diversity of E. coli 's numerous strains is not as vast as previously thought, inspiring hopes that a global vaccine can be developed.

Ocular Therapeutix announces Phase II results of sustained-released eye care drug

Eye care company Ocular Therapeutix today announced the results of its Phase II trial of its Sustained Release Dexamethasone aimed at treating allergic conjunctivitis. The 42-day randomized, double-blind study of 68 patients showed that patients on the candidate had lower ocular itching and conjunctival redness scores than those on the placebo, the company said.

Drug-loaded milk could offer oral HIV/AIDS prevention to children

HIV/AIDS prevention can be difficult in countries with limited resources, especially when it comes to the millions of affected children who are less likely to tolerate antiretroviral drugs. In an effort to overcome this challenge, researchers at Penn State University have developed a delivery system for the antiretroviral Ritonavir that uses a protein in cow's milk for oral administration of the drug.

Fujifilm says its flu drug is an Ebola solution in waiting

Fujifilm is confident its recently approved flu treatment can combat the spread of ebolavirus in West Africa, preparing for a surge in manufacturing as it waits on clinical trial results.

Arrowhead's midstage hep B data shows promise for RNA-based 'functional cure'

RNA interference specialist Arrowhead presented new data from an ongoing Phase IIa study of its hepatitis B treatment ARC-520, demonstrating a reduction of the disease's surface antigens in what the company says is a first for RNAi.